The association between the CCDC88A gene polymorphism at rs1437396 and alcohol use disorder, with or without major depression disorder.

Girdin is a protein involved in neuronal migration and hippocampal development. It is encoded by the coiled-coil domain-containing 88A (CCDC88A) gene, located on the short arm of chromosome 2 (2p). The CCDC88A gene is modulated by the intergenic single-nucleotide polymorphism (SNP) of the rs1437396, situated 9.5 kb downstream from its transcription stop site. As recent genome-wide research has associated the T allele of the SNP with increased risk of alcohol use disorder (AUD), we wanted to validate this finding in an independent cohort and to test further for an association with comorbid major depressive disorder (MDD). The study included 226 AUD patients (AUD group), 53 patients with comorbid MDD, and 391 controls selected randomly. The participants were genotyped for the rs1437396 polymorphism using the real-time polymerase chain reaction. The association between the rs1437396 polymorphism and increased risk of AUD and AUD+MDD was tested with logistic regression. Our results show significantly higher frequency of the T risk allele in the AUD group (p=0.027) and even higher in the AUD+MDD group (p=0.016). In conclusion, this is the first study that has validated the association between the rs1437396 polymorphism of the CCDC88A gene and AUD with or without MDD. Studies on larger samples of patients are needed to further investigate the mechanism of this association.

Análisis de polimorfismos APO-E en mujeres colombianas con osteoporosis y correlación con variables clínicas y sociales de riesgo / Polymorphismsof APO-E in Colombian women with osteoporosis: correlation among clinical and s9ocial risk variables

Varios estudios han demostrado la asociación de los polimorfismos de la apolipoproteína E (APO-E) con la osteoporosis, especialmente, la APO-E 4. Para analizar los polimorfismos APOE e identificar la asociación con variables clínicas y sociales, se realizó un estudio descriptivo de 32 mujeres con osteoporosis, provenientes de diferentes regiones de Colombia, mediante metodologías PCR y RFLP. Se observaron en osteoporosis, osteopenia y osteoporosis combinada con osteopenia frecuencias para el genotipo épsilon3/épsilon3 en el 84,3% (n=27), y en el 15,6% para los genotipos con el alelo épsilon4 (épsilon3/épsilon4=12,5%, n=4; épsilon4/épsilon4=3,1%, n=1); la misma tendencia se observó en la distribución por edad de la menopausia, épsilon3/épsilon3 en el 83,3% (n=25), y genotipos con el alelo épsilon4 en el 16,6% (n=5) (épsilon3/épsilon4=13,3%, n=4; épsilon4/épsilon4=3,3%, n=1). No hubo asociación de APO-E4 con estrato socioeconómico, fracturas, enfermedades o consumo de lácteos. Aunque no hubo efecto del alelo épsilon4 en la densidad mineral ósea (DMO) de la columna lumbar: épsilon4+/-(épsilon3/épsilon4 0,960±0,144 g/cm2); épsilon4+/+ (épsilon4/épsilon4 0,873±0,00 g/cm2); épsilon4-/- (épsilon3/épsilon3 0,858±0,160 g/cm2); p=0,49, ni en cuello femoral: épsilon4+/-(épsilon3/épsilon4 0,841±0,026 g/cm2); épsilon4+/+ (épsilon4/épsilon4 0,842±0,00 g/cm2); épsilon4- /- (épsilon3/épsilon3 0,735±0,013 g/cm2), p=0,14, al explorar las diferencias de medias de DMO en el cuello femoral, se observó una diferencia significativa, t=4,17 p=0,05. Estos datos confirman una frecuencia del alelo épsilon4 similar a lo reportado en poblaciones caucásicas y japonesas; se sugiere realizar estudios a gran escala para esclarecer el impacto de la APO-E sobre la DMO y su relación dosis-efecto.

Several studies have reported an association between apolipoprotein E polymorphisms and osteoporosis, specially the genotype APO-E4. In order to analyze the APO-E polymorphisms and to identify their association with clinical and social variables, a descriptive study was undertaken that included 32 women with osteoporosis, from different regions of Colombia. The polymorphisms were detected by PCR and RFLP methods. In osteopenia and osteoporosis combined with osteopenia were observed the genotype epsilon3/epsilon3 in the 84% (n=27), and 16% (epsilon3/epsilon4=12,5%, n=4; epsilon4/epsilon4=3,1%, n=1) for the genotypes bearing the epsilon4 allele. The same tendency was observed by age of the menopause,epsilon3/epsilon3 in the 83% (n=25), and the genotypes bearing the epsilon4 allele in the 17% (n=5)(epsilon3/epsilon4=13,3%, n=4; epsilon4/epsilon4=3,3%, n=1). No association of APO-E4 was detected with socioeconomic stratum, fracture, illness, surgeries, and milk consumption. No significant differences were observed in the bone mineral density (BMD) of the lumbar column between the genotypes with or without the epsilon4 allele epsilon4+/- (epsilon3/epsilon4 0.96±0.14 g/cm2); epsilon4+/+ (epsilon4/epsilon4 0.87±0.0 g/cm2); epsilon4-/- (epsilon3/epsilon3 0.86±0.16 g/cm2); p=0.49, and femoral bone mineral density epsilon4+/- (epsilon3/epsilon4 0.84±0.03 g/cm2); epsilon4+/+ (epsilon4/epsilon4 0.84±0.0 g/cm2); epsilon4-/- (epsilon3/epsilon3 0.74±0.01 g/cm2); p=0.014. However, when exploring the differences of BMD in the femoral neck, a significant difference was observed (t=4.17, p=0.05). These results confirm epsilon4 allele frequencies similar to those reported for caucasian and Japanese, subjects. Larger studies are necessary to elucidate the effect of APO-E in bone marrow and the dose-effect relation.